Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of C-type natriuretic peptide and amiodarone in Chinese patients with arrhythmia

Yajie Li¹, Yuhu Chun¹, Hongwei Dang¹, Kai Chen², Xia Wang¹

¹Department of Cardiology, BaoJi Central Hospital, Shaanxi Province 721008, China; ²Department of Respiratory Medicine, BaoJi Central Hospital, Shaanxi Province 721008, China.

For correspondence:- Xia Wang Email: weiming13@126.com Tel:+8615129505590

Accepted: 26 September 2022 Published: 28 October 2022

Citation: Li Y, Chun Y, Dang H, Chen K, Wang X. Effect of C-type natriuretic peptide and amiodarone in Chinese patients with arrhythmia. Trop J Pharm Res 2022; 21(10):2195-2201 doi: 10.4314/tjpr.v21i10.21

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To compare the effect of C-type natriuretic peptide and amiodarone in Chinese patients with arrhythmia.

Method: Chinese men and women aged 18 to 65 years with premature ventricular complexes (PVCs), were administered C-type natriuretic peptide (CNP) - test group or amiodarone (study group) in ratio of 1:1 for 96 h. Patients in CNP group received infusion of synthetic human CNP (10 pmol/kg/min) for an initial 2 h, and then for 30 min every day until discharge. Patients in amiodarone group received initial dose of 1000 mg over the first 24 h. Change in PVCs from baseline was the primary efficacy endpoint. Secondary efficacy endpoint includes: change in PVCs-related symptom scores from baseline, change in ejection fraction of left ventricle (LV), endâ€‘diastolic diameter of LV, and cardiac events as composite outcome (CCE). The effect of both treatments on hemodynamic and electrocardiography parameters, and safety were evaluated. Data from 200 patients were analyzed.

Results: The CNP showed significantly greater decrease in the number of PVCs when compared to amiodarone (p < 0.005). Moreover, CNP was superior in alleviating PVCs- related symptoms when compared to amiodarone (p < 0.005). A similar trend of favorable effect of CNP was observed for other endpoints.

Conclusion: The C-type natriuretic peptide offers significantly greater benefits of suppressing PVCs and related symptoms, and demonstrates significantly greater improvement of cardiac function and clinical outcome. Thus, CNP can be considered for further investigation as a suitable alternative in the management of ventricular arrhythmia with PVC among Chinese patients.

Keywords: C-type natriuretic peptide, Amiodarone, Ventricular arrhythmia, Premature ventricular complexes